{"id":46073,"date":"2025-11-07T14:16:53","date_gmt":"2025-11-07T06:16:53","guid":{"rendered":"https:\/\/flcube.com\/?p=46073"},"modified":"2025-11-07T14:16:54","modified_gmt":"2025-11-07T06:16:54","slug":"beone-medicines-posts-1-4-b-q3-2025-revenue-driven-by-brukinsa-momentum","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46073","title":{"rendered":"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum"},"content":{"rendered":"\n<p><strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG:\u202f6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>) released its third\u2011quarter 2025 financial results, reporting <strong>total revenue of $1.4\u202fbillion<\/strong>, up 40\u202f% from the $1.0\u202fbillion recorded in Q3\u202f2024. 100\u202f% of the revenue came from product sales, with the <strong>U.S. market<\/strong> remaining the dominant driver.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-financial-highlights\">Key Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q3\u202f2025<\/th><th>Q3\u202f2024<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total revenue<\/strong><\/td><td><strong>$1.4\u202fB<\/strong><\/td><td>$1.0\u202fB<\/td><td><strong>+40\u202f%<\/strong><\/td><\/tr><tr><td><strong>U.S. product revenue<\/strong><\/td><td>$743\u202fM<\/td><td>$504\u202fM<\/td><td><strong>+47\u202f%<\/strong><\/td><\/tr><tr><td><strong>BRUKINSA (U.S.) sales<\/strong><\/td><td>$739\u202fM<\/td><td>$503\u202fM<\/td><td><strong>+47\u202f%<\/strong><\/td><\/tr><tr><td><strong>BRUKINSA (Europe) sales<\/strong><\/td><td>$163\u202fM<\/td><td>$97\u202fM<\/td><td><strong>+68\u202f%<\/strong><\/td><\/tr><tr><td><strong>TEVIMBRA sales (global)<\/strong><\/td><td>$191\u202fM<\/td><td>$163\u202fM<\/td><td><strong>+17\u202f%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BRUKINSA (zanubrutinib)<\/strong> continued to lead the BTK\u2011inhibitor class, expanding new\u2011patient market share across all approved indications.<\/li>\n\n\n\n<li>European growth was broad\u2011based, with double\u2011digit gains in Germany, Italy, Spain, France and the United Kingdom.<\/li>\n\n\n\n<li><strong>TEVIMBRA (tislelizumab)<\/strong> contributed a modest but steady uplift, reflecting growing adoption in its oncology label portfolio.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-transactions\">Strategic Transactions<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Royalty Pharma Sale<\/strong> \u2013 BeOne entered a definitive agreement to sell its royalty rights on global (non\u2011China) sales of <strong>tarlatamab (IMDELLTRA)<\/strong>, the Amgen\u2011licensed CD\u201128 agonist, for <strong>up to $950\u202fmillion<\/strong>. The upfront cash infusion is expected to fund late\u2011stage development programs and shareholder returns.<\/li>\n\n\n\n<li><strong>Patent Litigation Resolution<\/strong> \u2013 The U.S. Patent and Trademark Office\u2019s final written decision invalidated <strong>Pharmacyclics\u2019 U.S. Patent No.\u202f11,672,803<\/strong> covering BRUKINSA. Pharmacyclics, LLC elected not to appeal, ending the infringement lawsuit with finality and removing a significant legal cloud over BeOne\u2019s flagship product.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-outlook-amp-analyst-reaction\">Outlook &amp; Analyst Reaction<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Guidance:<\/strong> Management reaffirmed its 2025 full\u2011year revenue target of $5.5\u202fbillion\u2013$5.9\u202fbillion, citing continued BRUKINSA uptake and the upcoming launch of next\u2011generation indications.<\/li>\n\n\n\n<li><strong>Equity impact:<\/strong> BeOne shares rose <strong>2.4\u202f%<\/strong> in early trading following the earnings release.<\/li>\n\n\n\n<li><strong>Sell\u2011side commentary:<\/strong> Several analysts upgraded BeOne to \u201cBuy,\u201d highlighting the <strong>royalty\u2011sale proceeds<\/strong> and the <strong>patent\u2011clearance win<\/strong> as catalysts for cash\u2011flow acceleration and margin expansion.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements regarding BeOne Medicines\u2019 financial performance, strategic transactions and regulatory outlook. Actual results may differ due to risks and uncertainties detailed in the company\u2019s filings with the SEC, HKEX and SSE.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/BeOne_Q3_2025_Clinical_Trials_Appendix_FINAL.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BeOne_Q3_2025_Clinical_Trials_Appendix_FINAL.\"><\/object><a id=\"wp-block-file--media-86eff6f8-d450-4277-a9d9-9c275dd85523\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/BeOne_Q3_2025_Clinical_Trials_Appendix_FINAL.pdf\">BeOne_Q3_2025_Clinical_Trials_Appendix_FINAL<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/BeOne_Q3_2025_Clinical_Trials_Appendix_FINAL.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-86eff6f8-d450-4277-a9d9-9c275dd85523\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/BeOne_Q3_2025_Earnings_Deck_FINAL.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BeOne_Q3_2025_Earnings_Deck_FINAL.\"><\/object><a id=\"wp-block-file--media-eec5de99-c610-4790-92f0-b0e0876d41a4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/BeOne_Q3_2025_Earnings_Deck_FINAL.pdf\">BeOne_Q3_2025_Earnings_Deck_FINAL<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/BeOne_Q3_2025_Earnings_Deck_FINAL.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-eec5de99-c610-4790-92f0-b0e0876d41a4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) released its third\u2011quarter 2025 financial results, reporting&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46078,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[2092,27,4439,3046,848],"class_list":["post-46073","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-beone-medicines","tag-finanical-reports","tag-hkg-6160-2","tag-nasdaq-onc","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) released its third\u2011quarter 2025 financial results, reporting total revenue of $1.4\u202fbillion, up 40\u202f% from the $1.0\u202fbillion recorded in Q3\u202f2024. 100\u202f% of the revenue came from product sales, with the U.S. market remaining the dominant driver.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46073\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) released its third\u2011quarter 2025 financial results, reporting total revenue of $1.4\u202fbillion, up 40\u202f% from the $1.0\u202fbillion recorded in Q3\u202f2024. 100\u202f% of the revenue came from product sales, with the U.S. market remaining the dominant driver.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46073\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-07T06:16:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:16:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0707.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46073#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46073\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum\",\"datePublished\":\"2025-11-07T06:16:53+00:00\",\"dateModified\":\"2025-11-07T06:16:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46073\"},\"wordCount\":353,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46073#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0707.webp\",\"keywords\":[\"BeOne Medicines\",\"Finanical Reports\",\"HKG:\u202f6160\",\"NASDAQ: ONC\",\"SHA: 688235\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46073#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46073\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46073\",\"name\":\"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46073#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46073#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0707.webp\",\"datePublished\":\"2025-11-07T06:16:53+00:00\",\"dateModified\":\"2025-11-07T06:16:54+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) released its third\u2011quarter 2025 financial results, reporting total revenue of $1.4\u202fbillion, up 40\u202f% from the $1.0\u202fbillion recorded in Q3\u202f2024. 100\u202f% of the revenue came from product sales, with the U.S. market remaining the dominant driver.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46073#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46073\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46073#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0707.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0707.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46073#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) released its third\u2011quarter 2025 financial results, reporting total revenue of $1.4\u202fbillion, up 40\u202f% from the $1.0\u202fbillion recorded in Q3\u202f2024. 100\u202f% of the revenue came from product sales, with the U.S. market remaining the dominant driver.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46073","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) released its third\u2011quarter 2025 financial results, reporting total revenue of $1.4\u202fbillion, up 40\u202f% from the $1.0\u202fbillion recorded in Q3\u202f2024. 100\u202f% of the revenue came from product sales, with the U.S. market remaining the dominant driver.","og_url":"https:\/\/flcube.com\/?p=46073","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-07T06:16:53+00:00","article_modified_time":"2025-11-07T06:16:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0707.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46073#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46073"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum","datePublished":"2025-11-07T06:16:53+00:00","dateModified":"2025-11-07T06:16:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46073"},"wordCount":353,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46073#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0707.webp","keywords":["BeOne Medicines","Finanical Reports","HKG:\u202f6160","NASDAQ: ONC","SHA: 688235"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46073#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46073","url":"https:\/\/flcube.com\/?p=46073","name":"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46073#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46073#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0707.webp","datePublished":"2025-11-07T06:16:53+00:00","dateModified":"2025-11-07T06:16:54+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA: 688235) released its third\u2011quarter 2025 financial results, reporting total revenue of $1.4\u202fbillion, up 40\u202f% from the $1.0\u202fbillion recorded in Q3\u202f2024. 100\u202f% of the revenue came from product sales, with the U.S. market remaining the dominant driver.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46073#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46073"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46073#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0707.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0707.webp","width":1080,"height":608,"caption":"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46073#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines Posts $1.4\u202fB Q3\u202f2025 Revenue, Driven by BRUKINSA Momentum"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0707.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46073"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46073\/revisions"}],"predecessor-version":[{"id":46081,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46073\/revisions\/46081"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46078"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}